clinical-stage company

Scilex subsidiaries sell ACEA Pharma to Phoenix Asia for $1B in stock; retain 82% ownership post-Nasdaq listing in Q2 2026.

Sionna director sells $2.5M in stock (2% of holdings) during 215% surge; $310M cash position supports pipeline through 2028.

MoonLake Immunotherapeutics CEO Jorge Santos da Silva sold $2.8M in shares, reducing holdings 4.9%. Stock down 47% year-over-year amid disappointing trial results.

Spyre Therapeutics prices $403M stock offering at $62/share with 6.5M shares, expected to close April 16, 2026. Prominent underwriters include Goldman Sachs and Jefferies.

Beam Therapeutics CEO John Evans sold 30,078 shares for $739K via pre-planned tax obligation. Strong 2025 revenue growth and $1.2B cash reserves indicate company health.

Biotech hedge fund BVF Partners sold $63M in MoonLake shares, trimming its stake 78% while retaining 15.9M shares, amid broader sector volatility.

ENAVATE deepens Zenas BioPharma stake to $142.3M. Key catalyst: obexelimab Phase 2 lupus data and Q2 2026 FDA submission.

Soleus Capital significantly increased its Celcuity stake to 1.8 million shares, making it their third-largest position worth $180 million as the biotech stock surged 745% yearly.